The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
The gut microbiota metabolism of pomegranate or walnut ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkers: Comparison between normoweight, overweight-obesity and metabolic syndrome
Open accessAbstract
BACKGROUND & AIMS Urolithins are microbial metabolites produced after consumption of ellagitannin-containing foods such as pomegranates and walnuts. Parallel to isoflavone-metabolizing phenotypes, ellagitannin-metabolizing phenotypes (urolithin metabotypes A, B and 0; UM-A, UM-B and UM-0, respectively) can vary among individuals depending on their body mass index (BMI), but correlations between urolithin metabotypes (UMs) and cardiometabolic risk (CMR) factors are unexplored. We investigated the association between UMs and CMR factors in individuals with different BMI and health status. METHODS UM was identified using UPLC-ESI-qToF-MS in individuals consuming pomegranate or nuts. The associations between basal CMR factors and the urine urolithin metabolomic signature were explored in 20 healthy normoweight individuals consuming walnuts (30 g/d), 49 healthy overweight-obese individuals ingesting pomegranate extract (450 mg/d) and 25 metabolic syndrome (MetS) patients consuming nuts (15 g-walnuts, 7.5 g-hazelnuts and 7.5 g-almonds/d). RESULTS Correlations between CMR factors and urolithins were found in overweight-obese individuals. Urolithin-A (mostly present in UM-A) was positively correlated with apolipoprotein A-I (P ≤ 0.05) and intermediate-HDL-cholesterol (P ≤ 0.05) while urolithin-B and isourolithin-A (characteristic from UM-B) were positively correlated with total-cholesterol, LDL-cholesterol (P ≤ 0.001), apolipoprotein B (P ≤ 0.01), VLDL-cholesterol, IDL-cholesterol, oxidized-LDL and apolipoprotein B:apolipoprotein A-I ratio (P ≤ 0.05). In MetS patients, urolithin-A only correlated inversely with glucose (P ≤ 0.05). Statin-treated MetS patients with UM-A showed a lipid profile similar to that of healthy normoweight individuals while a poor response to lipid-lowering therapy was observed in MB patients. CONCLUSIONS UMs are potential CMR biomarkers. Overweight-obese individuals with UM-B are at increased risk of cardiometabolic disease, whereas urolithin-A production could protect against CMR factors. Further research is warranted to explore these associations in larger cohorts and whether the effect of lipid-lowering drugs or ellagitannin-consumption on CMR biomarkers depends on individuals' UM. CLINICAL TRIAL REGISTRY NUMBERS AND WEBSITES NCT01916239 (https://clinicaltrials.gov/ct2/show/NCT01916239) and ISRCTN36468613 (http://www.isrctn.com/ISRCTN36468613).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Lamarche, B., Moorjani, S., Lupien, P. J., Cantin, B., Bernard, P.-M., Dagenais, G. R., & Despre´s, J.-P. (1996) · Circulation · doi:10.1161/01.cir.94.3.273 · Cited by 476
Selma, M. V., Beltrán, D., García-Villalba, R., Espín, J. C., & Tomás-Barberán, F. A. (2014) · Food Funct. · doi:10.1039/c4fo00092g · Cited by 304
Self-citationGonzález‐Sarrías, A., Giménez‐Bastida, J. A., García‐Conesa, M. T., Gómez‐Sánchez, M. B., García‐Talavera, N. V., Gil‐Izquierdo, A., Sánchez‐Álvarez, C., Fontana‐Compiano, L. O., Morga‐Egea, J. P., Pastor‐Quirante, F. A., et al. (2010) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900152 · Cited by 212
Self-citationCollins, H. L., Drazul-Schrader, D., Sulpizio, A. C., Koster, P. D., Williamson, Y., Adelman, S. J., Owen, K., Sanli, T., & Bellamine, A. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.10.108 · Cited by 189
Cited by
Bioactivity of dietary polyphenols: The role of metabolites
Luca, S. V., Macovei, I., Bujor, A., Miron, A., Skalicka-Woźniak, K., Aprotosoaie, A. C., & Trifan, A. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1546669 · Cited by 718
The gut microbiota: a key factor in the therapeutic effects of (poly)phenols
Espín, J. C., González-Sarrías, A., & Tomás-Barberán, F. A. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.04.033 · Cited by 603
Self-citationMeslier, V., Laiola, M., Roager, H. M., De Filippis, F., Roume, H., Quinquis, B., Giacco, R., Mennella, I., Ferracane, R., Pons, N., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-320438 · Cited by 583
Corrêa, T. A. F., Rogero, M. M., Hassimotto, N. M. A., & Lajolo, F. M. (2019) · Frontiers in Nutrition · doi:10.3389/fnut.2019.00188 · Cited by 316
Urolithins: a Comprehensive Update on their Metabolism, Bioactivity, and Associated Gut Microbiota
García‐Villalba, R., Giménez‐Bastida, J. A., Cortés‐Martín, A., Ávila‐Gálvez, M. Á., Tomás‐Barberán, F. A., Selma, M. V., Espín, J. C., & González‐Sarrías, A. (2022) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202101019 · Cited by 302
Self-citation
Metadata
- Authors
- Selma, M. V., González-Sarrías, A., Salas-Salvadó, J., Andrés-Lacueva, C., Alasalvar, C., Örem, A., Tomás-Barberán, F. A., & Espín, J. C.
- Venue
- Clinical Nutrition
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 37
- Issue
- 3
- Pages
- 897-905
- ISSN
- 0261-5614 (ISSN-L)
- OpenAlex
- W2595992107
- Cited by
- 162
- References
- 5
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.